Blood Volatile Organic Compounds As Potential Biomarkers for Amyotrophic Lateral Sclerosis: an Animal Study in the SOD1 G93A Mouse

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2014 Apr 10

PMID 24715356

Citations 3

Authors

Hongquan Jiang

Changsong Wang

Ming Ren

Xiang Yin

Chunjie Chi

Lei Guo

Chaofu Ke

Honglin Feng

Enyou Li

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapid progressive motor neuron disease. Currently, there are no specific or reliable biomarkers for the diagnosis of this disease, and there are no effective medical treatments. The early diagnosis and treatment of this disease has the potential to prolong the survival of ALS patients, but typically, approximately 1 year passes between the onset of symptoms and the diagnosis of this disease. Therefore, there is an urgent need to find specific biomarkers to enable early diagnosis and therapeutic intervention in this disease. Analyzing the volatile organic compounds (VOCs) present in the blood and exhaled breath is a useful and convenient approach for investigating potential biomarkers. In this study, we examined the VOCs present in blood samples from copper zinc superoxide dismutase 1 (SOD1) glycine to alanine mutation at position 93 (G93A) mice to determine whether a specific biomarker pattern exists in these transgenic mice. Blood samples from ALS mice and their age-matched littermates were analyzed using gas chromatography-mass spectrometry. A total of 12 independent compounds associated with oxidative stress were identified at the early stage of disease. The data show that there is a specific pattern of blood VOCs in ALS mice that could potentially be used as biomarkers that could improve the diagnosis of this disease. Furthermore, these compounds could also potentially be used to monitor the response to neuroprotective agents and to help us better understand the underlying mechanisms of ALS.

Citing Articles

Application of Electronic-Nose Technologies and VOC-Biomarkers for the Noninvasive Early Diagnosis of Gastrointestinal Diseases .

Wilson A Sensors (Basel). 2018; 18(8).

PMID: 30096939 PMC: 6111575. DOI: 10.3390/s18082613.

From animal models to human disease: a genetic approach for personalized medicine in ALS.

Picher-Martel V, Valdmanis P, Gould P, Julien J, Dupre N Acta Neuropathol Commun. 2016; 4(1):70.

PMID: 27400686 PMC: 4940869. DOI: 10.1186/s40478-016-0340-5.

Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients.

Wang C, Li M, Jiang H, Tong H, Feng Y, Wang Y Sci Rep. 2016; 6:26120.

PMID: 27212435 PMC: 4876505. DOI: 10.1038/srep26120.

References

Kuzma M, Jamrozik Z, Baranczyk-Kuzma A . Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta. 2005; 364(1-2):217-21. DOI: 10.1016/j.cccn.2005.07.008. View

Miller R, Mitchell J, Moore D . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012; (3):CD001447. PMC: 7055506. DOI: 10.1002/14651858.CD001447.pub3. View

Miana-Mena F, Munoz M, Yague G, Mendez M, Moreno M, Ciriza J . Optimal methods to characterize the G93A mouse model of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6(1):55-62. DOI: 10.1080/14660820510026162. View

Halliwell B . Oxidative stress and neurodegeneration: where are we now?. J Neurochem. 2006; 97(6):1634-58. DOI: 10.1111/j.1471-4159.2006.03907.x. View

Gordon S, Wallace L, Brinkman M, Callahan P, Kenny D . Volatile organic compounds as breath biomarkers for active and passive smoking. Environ Health Perspect. 2002; 110(7):689-98. PMC: 1240915. DOI: 10.1289/ehp.02110689. View

Hall E, Andrus P, Oostveen J, Fleck T, Gurney M . Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res. 1998; 53(1):66-77. DOI: 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.0.CO;2-H. View

Turner M, Kiernan M, Leigh P, Talbot K . Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2008; 8(1):94-109. DOI: 10.1016/S1474-4422(08)70293-X. View

Bento-Abreu A, Van Damme P, Van Den Bosch L, Robberecht W . The neurobiology of amyotrophic lateral sclerosis. Eur J Neurosci. 2010; 31(12):2247-65. DOI: 10.1111/j.1460-9568.2010.07260.x. View

Rozen S, Cudkowicz M, Bogdanov M, Matson W, Kristal B, Beecher C . Metabolomic analysis and signatures in motor neuron disease. Metabolomics. 2008; 1(2):101-108. PMC: 2553219. DOI: 10.1007/s11306-005-4810-1. View

10.

Bowser R, Lacomis D . Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve. 2009; 40(5):753-62. PMC: 2836583. DOI: 10.1002/mus.21488. View

11.

Miana-Mena F, Gonzalez-Mingot C, Larrode P, Munoz M, Olivan S, Fuentes-Broto L . Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis. J Neurol. 2010; 258(5):762-9. DOI: 10.1007/s00415-010-5825-8. View

12.

Tandan R, Bradley W . Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985; 18(3):271-80. DOI: 10.1002/ana.410180302. View

13.

Kanner J, German J, Kinsella J . Initiation of lipid peroxidation in biological systems. Crit Rev Food Sci Nutr. 1987; 25(4):317-64. DOI: 10.1080/10408398709527457. View

14.

Tisch U, Schlesinger I, Ionescu R, Nassar M, Axelrod N, Robertman D . Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. Nanomedicine (Lond). 2012; 8(1):43-56. DOI: 10.2217/nnm.12.105. View

15.

Knight J . Free radicals: their history and current status in aging and disease. Ann Clin Lab Sci. 1998; 28(6):331-46. View

16.

Shaw P . Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005; 76(8):1046-57. PMC: 1739758. DOI: 10.1136/jnnp.2004.048652. View

17.

Hassanein M, Callison J, Callaway-Lane C, Aldrich M, Grogan E, Massion P . The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012; 5(8):992-1006. PMC: 3723112. DOI: 10.1158/1940-6207.CAPR-11-0441. View

18.

Simpson E, Henry Y, Henkel J, Smith R, Appel S . Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology. 2004; 62(10):1758-65. DOI: 10.1212/wnl.62.10.1758. View

19.

Davies K, Delsignore M, Lin S . Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem. 1987; 262(20):9902-7. View

20.

Andersen J . Oxidative stress in neurodegeneration: cause or consequence?. Nat Med. 2004; 10 Suppl:S18-25. DOI: 10.1038/nrn1434. View